Model DetailsLung carcinoma
Model Name |
Lung carcinoma | Strain |
CD-1 |
Tumor Inducing Agent(s) |
None (spontaneous) |
Tumor Synonyms |
lung, bronchiolo-alveolar carcinoma • lung carcinoma • lung, alveolar-bronchiolar carcinoma • bronchiolar/alveolar carcinoma • lung, carcinoma, bronchiolar-alveolar • lung tumor • bronchiolo-alveolar carcinoma • alveolar-bronchiolar carcinoma |
Strain Synonyms |
outbred CD-1 • Swiss CD-1® • CD1 nontransgenic • Charles River CD-1 • Swiss CD-1 • Crl:CD-1®(ICR) • outbred CD1 • (Swiss) CD-1 • CD1 • Crl:CD-1(ICR)BR • ICR Crj:CD-1 • random-bred Crl:CD-1(ICR)BR • CD-1 outbred • Crl:CD-1 (ICR) BR • Crj:CD-1(ICR) • ICR(CD-1) • Crl: CD-1 (ICR) BR • ICR |
| Organ Affected | Sex | Frequency | Age Of Detection | Additional Information Expand all Collapse all | Reference |
|---|---|---|---|---|---|
| Lung | Male |
6.9% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
9.8% (5 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
5.8% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
3.9% (2 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
5.6% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
3.9% (2 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
4.1% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
5.9% (3 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
6.7% (4 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
13.2% (9 of 68 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
1.7% (1 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
7.4% (5 of 68 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
7.8% (5 of 64 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
11.8% (6 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
3.2% (2 of 63 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
2.0% (1 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
2.5% (18 of 725 mice) |
|
Chandra M, Toxicol Lett 1992 Jun;61(1):67-74 | |
| Lung | Female |
1.5% (11 of 725 mice) |
|
Chandra M, Toxicol Lett 1992 Jun;61(1):67-74 | |
| Lung | Male |
10% (6 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lymph node | Male |
0% (0 of 6 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Thoracic cavity | Male |
17% (1 of 6 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Male |
5.0% (3 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lymph node | Male |
0% (0 of 3 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Thoracic cavity | Male |
0% (0 of 3 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Female |
5.0% (3 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lymph node | Female |
0% (0 of 3 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Thoracic cavity | Female |
0% (0 of 3 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Female |
10% (6 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lymph node | Female |
17% (1 of 6 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Thoracic cavity | Female |
17% (1 of 6 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Male |
6.7% (4 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Blood vessel - Aorta | Male |
25% (1 of 4 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lymph node | Male |
25% (1 of 4 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Thoracic cavity | Male |
25% (1 of 4 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Female |
6.7% (4 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Blood vessel - Aorta | Female |
0% (0 of 4 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lymph node | Female |
0% (0 of 4 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Thoracic cavity | Female |
0% (0 of 4 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Male |
3.2% (1 of 31 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
12.5% (2 of 16 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
20% (1 of 5 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
14.3% (3 of 21 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
7.7% (4 of 52 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
3.2% (1 of 31 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
0% (0 of 12 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
18.2% (2 of 11 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
8.7% (2 of 23 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
5.6% (3 of 54 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |